In this multicentre , randomised phase III trial with 22 design , patients with FIGO stage IIb-IV EOC were randomised to six cycles PCw ( paclitaxel 90mg/m ( 2 ) , cisplatin 70mg/m ( 2 ) or carboplatin AUC 4 ) or three cycles PC3w ( paclitaxel 175mg/m ( 2 ) , cisplatin 75mg/m ( 2 ) or carboplatin AUC 6 ) , followed by either three or six cycles PC3w .